Rem was only ever able to satisfy a small fraction

Rem was only ever able to satisfy a small fraction of a demand. That's why I've been trying to explain that gilead was a none-issue for several weeks now. What people need to understand is that these small molecules are made from reagents. The more extensive the chemical process that goes into synthesis (and believe me when I say rem is not an easy compound to synthesize, I can expland if you like), the more unique and hard to come by reagents are necessary. Some of these reagents involve precious metals, others are hard to make in and of themselves. Therefore, everything else aside, the bottleneck for rem will always be reagent availability. There is no way and no amount of money that will get around that. It's a simple basic fact like gravity.

Don't get me wrong, leronlimab has its own bottlenecks, you need space to grow cells and you need your own equipment and reagents to purify antibodies from those cells, but in terms of head to head competition or one rendering the other obsolete, there is close to if not 0% chance of that happening in any reasonable time frame.